Charles Russell Speechlys advises Kreos and SVB on refinancing of £20 million growth capital investment to Mereo BioPharma
Charles Russell Speechlys LLP advised Kreos Capital V (UK) Limited and Silicon Valley Bank on the refinancing of their £20 million growth capital investment to Mereo BioPharma Group plc (“Mereo BioPharma”), a clinical stage UK-based biopharmaceutical company listed on the AIM market of the London Stock Exchange.
Mereo BioPharma focuses on the development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare diseases. The portfolio currently consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies.
The Charles Russell Speechlys core team comprised Rossana Conti (Legal Director), Amelly Kok (Associate) and Charlie Searle (Corporate Trainee) from our Corporate Team, and Daniel Sullivan (Partner) and Susan Mitchell (Senior Associate) from our Banking & Finance Team.
News & Insights
Charles Russell Speechlys releases H2 2019 deal highlights
Our highlights over the past 6 months are now available.
PremFlix: the Premier League’s plans to introduce a ‘Netflix-style’ OTT service
Last week it was reported that English football’s top flight is planning to offer its own bespoke streaming service in some territories.
Charles Russell Speechlys advises Growthpoint Investec African Properties on its acquisition of the RMB Westport Real Estate Development Fund
Charles Russell Speechlys advised Growthpoint Investec African Properties on its third acquisition of RMB Westport.